Coronavirus Vaccine Technology Landscape Updates

Mar 6, 2026 | New Publication for SARS-CoV-2 Candidate
Oyedele 2026 describes research into AZD6563 (AstraZeneca), an mRNA, virus-like particle SARS-CoV-2 vaccine in Phase 1 clinical development.

Mar 6, 2026 | New Publication for SARS-CoV-2 Candidate
Elsharkawy 2025 describes preclinical research into GEO-CM04S1 (Geovax), a viral vector SARS-CoV-2 candidate in Phase 2 clinical development.

Mar 6, 2026 | New Publications for SARS-CoV-2 Candidate
Chen 2025 and Chen 2024 describe research into NB2155 (Guangzhou Medical University), a viral vector SARS-CoV-2 candidate in Phase 1 clinical development.

Mar 6, 2026 | SARS-CoV-2 Candidate Approval
SARS-CoV-2 vaccine mRNA-1283 (Moderna), also known as mNEXSPIKE, has been approved for use in Australia, Canada, the European Union, and the United States.

Feb 16, 2026 | Broadly Protective Vaccine Candidate Addition
Yang 2026 describe research into HR1-VV-HR2-VS (University of Science and Technology of China), a broadly protective, protein subunit vaccine in preclinical development.

Feb 16, 2026 | Broadly Protective Vaccine Candidate Addition
Kelvin 2026 describe research into VIDO-4500-4503 (University of Calgary, University of Pittsburgh, and University of Saskatchewan), a broadly protective, protein subunit vaccine in preclinical development.

Feb 16, 2026 | SARS-CoV-2 Vaccine Candidate Addition
Altina 2026 describe research into SolaVAX (Colorado State University), an inactivated SARS-CoV-2 vaccine in preclinical development.

Feb 16, 2026 | New Publication for Broadly Protective Vaccine Candidate
Srivastava 2026 describes the design of Sarbeco-RBD-cocktail (Indian Institute of Science, Institute of Microbial Technology, Mynvax, and National Institute of Pharmaceutical Education and Research), a broadly protective, protein subunit vaccine in preclinical development.

Feb 9, 2026 | MERS Vaccine Candidate Addition
Powell 2026 describe research into MERS-1227-FNP (Vaccine Company, University of Utah, Colorado State University, University of Washington, and Alfaisal University), a nanoparticle MERS vaccine in preclinical development.

Feb 6, 2026 | Broadly Protective Vaccine Candidate Entry into Clinical Development
Broadly protective nanoparticle-based vaccine candidate GBP511 (SK Bioscience) has entered into a Phase I/II trial (NCT07280858).

Feb 4, 2026 | Broadly Protective Vaccine Candidate Addition
Te 2026 describe research into cb1 (University of Hong Kong, University of Melbourne, and Duke–National University of Singapore Medical School), a broadly protective live-attenuated vaccine in preclinical development.

Feb 4, 2026 | Broadly Protective Vaccine Candidate Addition
Shen 2026 describe research into VTT-Trivalent (Zhejiang University and Changping Laboratory), a broadly protective viral vector vaccine in preclinical development.

Jan 16, 2026 | SARS-CoV-2 Vaccine Candidate Addition
Vogel 2026 describe research into BNT162b3 (BioNTech and Pfizer), an mRNA vaccine in clinical development (Phase I/II clinical trial: NCT04537949).

Jan 16, 2026 | SARS-CoV-2 Vaccine Candidate Addition
Guan 2026 describe research into KP3-mRNA (Georgia State University), an mRNA SARS-CoV-2 vaccine in preclinical development.

Jan 16, 2026 | SARS-CoV-2 Vaccine Candidate Addition
Oyedele 2026 describe safety and immunogenicity data from a Phase 1 trial (NCT06147063) for AZD6563 (AstraZeneca), an mRNA virus-like particle SARS-CoV-2 vaccine in clinical development.

Jan 6, 2026 | SARS-CoV-2 Vaccine Candidate Update
The UK Medicines and Healthcare products Regulatory Agency approved Kostaive (Arcturus Therapeutics and Vinbiocare Biotechnology) for use in people 18 years of age and older. Kostaive has previously been approved in Japan and the EU/EEA.

Dec 15, 2025 | Broadly Protective Vaccine Candidate Addition
Halfmann 2025 describe research into VLP-S2-Clade2 and VLP-S2-Clade3 (University of Wisconsin–Madison, Georgia Institute of Technology, Weill Cornell Medicine, University of Tokyo, and National Center for Global Health and Medicine Research Institute), a virus-like particle broadly protective coronavirus vaccine in preclinical development.

Dec 5, 2025 | SARS-CoV-2 Vaccine Candidate Addition
Guo 2025 describe research into RBD-MnVac (National Center for Nanoscience and Technology of China, Guangdong Provincial Center for Disease Control and Prevention, Beijing Institute of Microbiology and Epidemiology, Beijing Institute of Technology, and University of Chinese Academy of Sciences), a protein subunit SARS-CoV-2 vaccine in preclinical development

Nov 21, 2025 | MERS Vaccine Candidate Addition
Khan 2026 and Hashem 2019 describe research into S1-F/CD40L (King Abdulaziz University, Saudi Food and Drug Authority, King Saud bin Abdulaziz University for Health Sciences, Qatar University, Jazan University, Health Canada, World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, University of Ottawa, and Taibah University), a protein subunit MERS vaccine in preclinical development.

Oct 30, 2025 | Broadly Protective Vaccine Candidate Addition
Dangi 2025 describe research into mRNA-OC43 (Harvard Medical School and Northwestern University), a nucleic acid-based broadly protective coronavirus vaccine in preclinical development.

Oct 30, 2025 | Announcement
CIDRAP launches Coronavirus Vaccine Technology Landscape. [Learn more]